Nucleo

Agentic AI for Oncology

Nucleo is building the first agentic AI platform for oncology, automating CT scan analysis to help oncologists characterize and treat tumors faster. The platform extracts key metrics including sarcopenia detection, body composition, lesion volume measurement, and RECIST classification — turning complex imaging data into actionable insights in seconds.

The typical American cancer patient waits 65 to 80 days before therapy begins. A four-week diagnostic delay increases mortality by 6 to 13 percent. Nucleo aims to compress this timeline to 10 days or less, fundamentally changing the speed at which cancer patients can begin treatment.

Speed, Accuracy, and Traction

Nucleo's AI achieves 98% agreement with medical experts while processing scans 2,500 times faster than manual analysis. The platform is already generating revenue and powering studies at Stanford Hospital, Cedars-Sinai, UCI Health, and Weill Cornell Medicine.

The company raised a $4 million seed round and was accepted into Y Combinator's Fall 2025 batch, positioning it to scale its automated diagnostics platform across the oncology landscape.

About Angelica Iacovelli & Luca Pegolotti

Angelica Iacovelli (CEO) holds BS and MS degrees in Mathematical Engineering from Politecnico di Milano. She conducted research at Stanford where she worked on cardiovascular modeling using graph neural networks, LSTMs, and Transformers. Her models are now part of NVIDIA's scientific computing libraries. She was named to the Nova 111 list as one of the most influential Italians under 35 in software.

Luca Pegolotti (CTO) holds a BSc from Politecnico di Milano and MSc/PhD from EPFL. He conducted research at Stanford School of Medicine and was a main maintainer of the Vascular Model Repository. Previously part of Apple Health AI, he worked on physics-informed machine learning. The two began collaborating at Stanford's Department of Medicine in 2023.

YC F25

Accelerator

Stanford

Research

NVIDIA

Libraries

Nova 111

Honoree

Sources: Public press releases, SEC and state business filings, published interviews, news coverage, and company disclosures.

Agentic AI for Oncology

Speed, Accuracy, and Traction

About Angelica Iacovelli & Luca Pegolotti

Founder Media Mentions for Angelica Iacovelli & Luca Pegolotti